Edit
Berkeley HeartLab
http://www.bhlinc.com/Last activity: 18.03.2010
Probably Closed - Reference to Quest Diagnostics Inc.: Leading Provider of Diagnostic Information Services
At Quest, we're working together to create a healthier world, one life at a time.
Location: United States, California, Burlingame
Employees: 201-500
Investors 1
| Date | Name | Website |
| - | Steelpoint... | steelpoint... |
Mentions in press and media 5
| Date | Title | Description |
| 18.03.2010 | Cardiac biomarker gets second life | By Mary Vanac Jake Orville always thought the cardiac inflammation biomarker developed by Dr. Stanley Hazen and his colleagues at the Cleveland Clinic was a valuable and proven technology. But his efforts to make it a commercial success for... |
| 17.03.2010 | Cleveland HeartLab: How to go to market with diagnostic test? | Based on Hazen’s research, Cleveland Clinic spin-off company PrognostiX had commercialized a test for myeloperoxidase–an enzyme that indicates inflammation in the artery walls of the heart, which can predict fatal heart attacks or strokes. ... |
| 20.09.2007 | Life sciences briefing: Thursday, Sept. 20, 2007 | Featured companies: Allergan, Athenahealth, Atria Genetics, Celera, Esprit Pharmaceuticals, Vida Diagnostics (NOTE: This item was posted on Friday, 9/21/07. I’ve backdated its timestamp to preserve the chronological order of the briefings.)... |
| 04.09.2007 | Life sciences briefing: Tuesday, Sept. 4, 2007 | Featured companies: Berkeley HeartLab, Celera Group, the Foundry, Molecular Vision, Morgenthaler Ventures Former genomics pioneer Celera Group buys Berkeley HealthLab for $195M — Rockville, Md.-based Celera Group, a one-time tie finisher in... |
| - | Cleveland HeartLab: How to go to market with diagnostic test? | Updated 4:29 p.m., March 18, 2010 The cardiac inflammation biomarker developed by Dr. Stanley Hazen and his colleagues at the Cleveland Clinic was a valuable and proven technology, thought Jake Orville, president and chief executive of Clev... |